PMID- 22799503
OWN - NLM
STAT- MEDLINE
DCOM- 20130213
LR  - 20181201
IS  - 1744-7658 (Electronic)
IS  - 1354-3784 (Linking)
VI  - 21
IP  - 10
DP  - 2012 Oct
TI  - Sorafenib for lung cancer: is the "Battle" still open?
PG  - 1445-8
AB  - In the recent years, the improved understanding of the biological relevance of 
      angiogenesis as a major cancer hallmark led to the development of a heterogeneous 
      group of agents targeting this key process. Among the anti-angiogenic drugs 
      (including monoclonal antibodies such as Bevacizumab, and other molecules with 
      different mechanism of action, such as the vascular disrupting agents Vadimezan), 
      the tyrosine kinase inhibitors (TKIs, Sorafenib, Sunitinib, Pazopanib, and 
      Axitinib), are commonly thought to inhibit angiogenesis through a most rational 
      and promising approach. In this regard, many tyrosine kinase inibitors, such as 
      Sorafenib, are multi-targeted, which allows for the inhibition of those multiple 
      functional pathways which are considered to be critical for both tumor 
      development and progression. Besides, this multi-targeted activity may 
      theoretically increase efficacy but also toxicity. As a member of this group, 
      Sorafenib has already been approved for the treatment of advanced renal cell 
      carcinoma (RCC) and hepatocellular carcinoma not suitable for locoregional 
      treatment, and it is currently under investigation for advanced non small cell 
      lung cancer (NSCLC), either alone or in combination with other 
      biological/cytotoxic agents.
FAU - Bria, Emilio
AU  - Bria E
FAU - Pilotto, Sara
AU  - Pilotto S
FAU - Tortora, Giampaolo
AU  - Tortora G
LA  - eng
PT  - Editorial
PT  - Research Support, Non-U.S. Gov't
DEP - 20120716
PL  - England
TA  - Expert Opin Investig Drugs
JT  - Expert opinion on investigational drugs
JID - 9434197
RN  - 0 (Angiogenesis Inhibitors)
RN  - 0 (Benzenesulfonates)
RN  - 0 (Phenylurea Compounds)
RN  - 0 (Protein Kinase Inhibitors)
RN  - 0 (Pyridines)
RN  - 25X51I8RD4 (Niacinamide)
RN  - 9ZOQ3TZI87 (Sorafenib)
SB  - IM
MH  - Angiogenesis Inhibitors/*therapeutic use
MH  - Benzenesulfonates/*therapeutic use
MH  - Carcinoma, Non-Small-Cell Lung/*drug therapy
MH  - Humans
MH  - Lung Neoplasms/*drug therapy
MH  - Niacinamide/analogs & derivatives
MH  - Phenylurea Compounds
MH  - Protein Kinase Inhibitors/*therapeutic use
MH  - Pyridines/*therapeutic use
MH  - Sorafenib
EDAT- 2012/07/18 06:00
MHDA- 2013/02/14 06:00
CRDT- 2012/07/18 06:00
PHST- 2012/07/18 06:00 [entrez]
PHST- 2012/07/18 06:00 [pubmed]
PHST- 2013/02/14 06:00 [medline]
AID - 10.1517/13543784.2012.707191 [doi]
PST - ppublish
SO  - Expert Opin Investig Drugs. 2012 Oct;21(10):1445-8. doi: 
      10.1517/13543784.2012.707191. Epub 2012 Jul 16.